FDA Intelligence | FDA

Advertising and Promotion

Jan 15, 2021
Latest FDA Intended Use Proposal Lacks Clarity, Falls Short on Legal Grounds, Comments Assert
Dec 30, 2020
Untitled Letter Provides Reminder of Basic Promotion Requirements
Dec 30, 2020
OPDP Issues Few Enforcement Letters in 2020 But They Have High Impact
Dec 7, 2020
Speaker Program Reexamination Needed After OIG Alert
Nov 23, 2020
Administration’s Most Favored Nation Pricing Plan Could Affect Industry Profitability
Oct 7, 2020
Tom Abrams’ Legacy at OPDP
Sep 11, 2020
New Normal for Ad Promo Is Likely the Old Normal
Sep 9, 2020
Limitations of Promotional Claims on Facial Masks Marketed under Emergency Use Authorizations
Aug 18, 2020
FDA’s 'Intended Use' Saga
Jul 27, 2020
Bad Ad Program At 10

Good Clinical Practice

Nov 15, 2018
Don’t Overlook Institutional Conflicts of Interest
Oct 30, 2018
Targeting Trial Recruitment Ads Can Be Tricky
May 2, 2018
Investigator Brochures in Early Trials Found Wanting
May 2, 2018
Audit Finds Non-Profits Fall Short on Trial Transparency Policies
Dec 8, 2017
More Transparency Needed in Nutrition Research
Nov 27, 2017
Practice of Excluding Prior Cancer Survivors from Clinical Trials Needs To Be Re-examined
Sep 15, 2017
NIH Releases Tools To Aid Researchers in Implementing Recent Trial Policy Changes
Aug 23, 2017
Number of FDA BIMO Inspections Drop Nearly 10 Percent in FY 2016
Aug 18, 2017
IRBs Need To Rethink Payments to Research Subjects

Food Labeling

Aug 11, 2020
It’s More than a New Graphic: How the New Nutrition Facts Panel Can Impact a Food’s Labeling, Marketing and Formulation
Sep 18, 2017
CFSAN Wants Ideas on Reducing Regulatory Burdens
Sep 18, 2017
FDA Allows First Qualified Health Claim To Prevent Food Allergy
Aug 15, 2017
Rulemakings on Bioengineered Food, Revision of Facts Panel Are ’Inactive’

FDA Regulation & Enforcement

Medical Devices

Copyright © Thompson FDA, a division of CBIS. All rights reserved.